An antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology retains neutralizing activity against the emerging BA.2 form of the Omicron coronavirus variant, according to data from a laboratory study cited by Vir on February 10.
Moderna Inc.’s Covid-19 vaccine produced neutralizing antibodies against emerging variants, including the Delta variant first identified in India, in a lab study.
Shares of Inovio climbed in trading after the company announced its DNA vaccine candidate for Covid-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.
An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. A study shows the two-drug combination is capable of suppressing HIV for months at a time.